https://diabetes.acponline.org/archives/2015/10/09/7.htm

Warning on risks of canagliflozin

The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density.


The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density. Clinicians should consider factors that contribute to fracture risk prior to starting patients on canagliflozin, which has also been linked to decreases in bone mineral density at the hip and lower spine. The FDA continues to evaluate the risk of bone fractures with other sodium-glucose cotransporter-2 inhibitors, such as dapagliflozin and empagliflozin, to determine if additional label changes or studies are needed, according to a safety communication.